Literature review and practical aspects on the management of oxaliplatin-associated toxicity

Clinical Colorectal Cancer

Volumn 11, Issue 2, 2012, Pages 93-100

  Hoff, Paulo M ^a,b   Saad, Everardo D ^c   Costa, Frederico ^a   Coutinho, Anelisa K ^d   Caponero, Ricardo ^e   Prolla, Gabriel ^f   Gansl, Rene C ^g  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Dendrix Research   (Brazil)

^d Clinica AMO   (Brazil)

^e Clínica de Oncologia Medica   (Brazil)

^f HOSPITAL MÃE DE DEUS   (Brazil)

^g Centro Paulista de Oncologia   (Brazil)

Author keywords

Colorectal neoplasms; Drug therapy; Drug toxicity; Neurotoxicity syndromes; Platinum compounds; Thrombocytopenia

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CALCIUM; CAPECITABINE; CARBAMAZEPINE; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; IRINOTECAN; MAGNESIUM; NEUROPROTECTIVE AGENT; OXALIPLATIN; PLACEBO; PREGABALIN; VENLAFAXINE; VERAPAMIL; XALIPRODEN;

ABDOMINAL PAIN; ADD ON THERAPY; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTERY SPASM; BRONCHOSPASM; CARDIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DISTAL PARESTHESIA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSESTHESIA; ERYTHEMA; FASCICULATION; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY SPASM; HUMAN; HYPEREMIA; HYPOTENSION; INFLAMMATION; INFUSION RELATED REACTION; INJECTION PAIN; LINGUAL PARESTHESIA; LIVER ARTERY SPASM; LIVER INJURY; LIVER METASTASIS; LIVER SINUSOID; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNGOLARYNGEAL DYSESTHESIA; PROGRESSION FREE SURVIVAL; PRURITUS; PSEUDOLARYNGOSPASM; RASH; REVIEW; RISK REDUCTION; SEROMA; SIDE EFFECT; SKIN EXFOLIATION; SPLENOMEGALY; STOMATITIS; THROMBOCYTOPENIA; TISSUE INJURY; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 84860717421     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.10.004     Document Type: Review

References (84)

1. American Cancer Society Cancer Facts & Figures 2009 2009 American Cancer Society Atlanta
2. A. Jemal, R. Siegel, J. Xu et al. Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
3. M.J. Hayat, N. Howlader, M.E. Reichman Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program Oncologist 12 2007 20 37 (Pubitemid 46143500)
4. R. Sauer, H. Becker, W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
5. W. Scheithauer, H. Rosen, G.V. Kornek Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 306 1993 752 755 (Pubitemid 23080053)
6. Nordic Gastrointestinal Tumor Adjuvant Therapy Group Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial J Clin Oncol 10 1992 904 911
7. A. Grothey, R.M. Goldberg A review of oxaliplatin and its clinical use in colorectal cancer Expert Opin Pharmacother 5 2004 2159 2170 (Pubitemid 39406117)
8. S. Gill, C.L. Loprinzi, D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 2004 1797 1806 (Pubitemid 41095169)
9. T. Andre, C. Boni, L. Mounedji-Boudiaf Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
10. A. de Gramont, J. Vignoud, C. Tournigand Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer Eur J Cancer 33 1997 214 219
11. T. Andre, C. Louvet, E. Raymond Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 9 1998 1251 1253 (Pubitemid 28552817)
12. T. Andre, M.A. Bensmaine, C. Louvet Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen J Clin Oncol 17 1999 3560 3568 (Pubitemid 29517928)
13. C. Tournigand, T. Andre, E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
14. C.J. Allegra, G. Yothers, M.J. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
15. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30 (Pubitemid 41095110)
16. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
17. B. Nordlinger, H. Sorbye, B. Glimelius Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016 (Pubitemid 351392040)
18. R. Adam, V. Delvart, G. Pascal Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 240 2004 644 657 discussion 57-8
19. T. Andre, C. Boni, M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
20. J.P. Kuebler, H.S. Wieand, M.J. O'Connell Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204 (Pubitemid 46954643)
21. D.G. Haller, J. Tabernero, J. Maroun Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer J Clin Oncol 29 2011 1465 1471
22. P.M. Hoff, C.S. Fuchs The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas Semin Oncol 30 2003 54 61 (Pubitemid 37264953)
23. D. Cunningham, N. Starling, S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
24. D. Cunningham, A.F. Okines, S. Ashley Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 362 2010 858 859
25. NCCN Oncology Practice Guidelines in Oncology. Esophageal Cancer version 2-2009.
26. T. Conroy, F. Desseigne, M. Ychou Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial J Clin Oncol 28 suppl 2010 15 (abstract 4010)
27. D. Machover, E. Diaz-Rubio, A. de Gramont Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 1996 95 98 (Pubitemid 26051870)
28. E. Cvitkovic, M. Bekradda Oxaliplatin: a new therapeutic option in colorectal cancer Semin Oncol 26 1999 647 662 (Pubitemid 30013272)
29. J. Cassidy, J.L. Misset Oxaliplatin-related side effects: characteristics and management Semin Oncol 29 2002 11 20 (Pubitemid 35191037)
30. L. Gamelin, O. Capitain, A. Morel Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway Clin Cancer Res 13 2007 6359 6368 (Pubitemid 350075025)
31. T. Lecomte, B. Landi, P. Beaune Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy Clin Cancer Res 12 2006 3050 3056 (Pubitemid 43837350)
32. R.G. Webster, K.L. Brain, R.H. Wilson Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels Br J Pharmacol 146 2005 1027 1039 (Pubitemid 41722176)
33. S.B. Park, D. Goldstein, C.S. Lin Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity J Clin Oncol 27 2009 1243 1249
34. F. Grolleau, L. Gamelin, M. Boisdron-Celle A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J Neurophysiol 85 2001 2293 2297 (Pubitemid 32440704)
35. E. Gamelin, L. Gamelin, L. Bossi Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures Semin Oncol 29 2002 21 33 (Pubitemid 35191038)
36. L. Pendyala, P.J. Creaven, R. Perez Intracellular glutathione and cytotoxicity of platinum complexes Cancer Chemother Pharmacol 36 1995 271 278
37. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (v4.03: June 14, 2010). U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute [Web site] http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf Accessed November 24, 2010
38. ® prescribing information [Web site] http://productssanofi-aventisus/eloxatin/eloxatinhtml Accessed: August 13, 2010
39. A. de Gramont, M. Buyse, J.C. Abrahantes Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer J Clin Oncol 25 2007 3224 3229 (Pubitemid 47325605)
40. F. Maindrault-Goebel, C. Tournigand, T. Andre Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer Ann Oncol 15 2004 1210 1214 (Pubitemid 39199307)
41. C. Tournigand, A. Cervantes, A. Figer OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study J Clin Oncol 24 2006 394 400 (Pubitemid 46630458)
42. B. Chibaudel, F. Maindrault-Goebel, G. Lledo Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study J Clin Oncol 27 2009 5727 5733
43. L. Gamelin, M. Boisdron-Celle, R. Delva Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clin Cancer Res 10 2004 4055 4061 (Pubitemid 38812481)
44. H.S. Hochster, A. Grothey, B.H. Childs Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J Clin Oncol 25 2007 4028 4029 (Pubitemid 47477294)
45. A. Grothey, L.L. Hart, K.M. Rowland Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial J Clin Oncol 26 suppl 2008 abstract 4010
46. L. Gamelin, M. Boisdron-Celle, A. Morel Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy J Clin Oncol 26 2008 1188 1189 author reply 1189-90
47. P.M. Hoff Oxaliplatin-related neurotoxicity: is chelation the solution? Nat Clin Pract Oncol 1 2004 78 79 (Pubitemid 40823746)
48. A. Grothey, D.A. Nikcevich, J.A. Sloan Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7 J Clin Oncol 29 2011 421 427
49. F.A. Levi, R. Zidani, J.M. Vannetzel Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial J Natl Cancer Inst 86 1994 1608 1617 (Pubitemid 24336347)
50. J. Fournier, R. Steinberg, T. Gauthier Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates Neuroscience 55 1993 629 641 (Pubitemid 23226109)
51. C. Lersch, R. Schmelz, F. Eckel Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer Clin Colorectal Cancer 2 2002 54 58 (Pubitemid 34704965)
52. P.L. Mitchell, D. Goldstein, M. Michael Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity Clin Colorectal Cancer 6 2006 146 151 (Pubitemid 44445750)
53. J.P. Durand, C. Brezault, F. Goldwasser Protection against oxaliplatin acute neurosensory toxicity by venlafaxine Anticancer Drugs 14 2003 423 425 (Pubitemid 36951792)
54. M.W. Saif, S. Hashmi Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer Cancer Chemother Pharmacol 61 2008 349 354 (Pubitemid 350275990)
55. M.W. Saif, K. Syrigos, K. Kaley Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy Anticancer Res 30 2010 2927 2933
56. J.P. Kuebler, L. Colangelo, M.J. O'Connell Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis Cancer 110 2007 1945 1950 (Pubitemid 350036852)
57. L. Rubbia-Brandt, V. Audard, P. Sartoretti Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 2004 460 466 (Pubitemid 38444550)
58. N.N. Mehta, R. Ravikumar, C.A. Coldham Effect of preoperative chemotherapy on liver resection for colorectal liver metastases Eur J Surg Oncol 34 2008 782 786
59. H. Nakano, E. Oussoultzoglou, E. Rosso Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 2008 118 124
60. J.N. Vauthey, T.M. Pawlik, D. Ribero Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 2006 2065 2072 (Pubitemid 46622116)
61. U.D. Bayraktar, S. Seren, Y. Bayraktar Hepatic venous outflow obstruction: three similar syndromes World J Gastroenterol 13 2007 1912 1927 (Pubitemid 46758856)
62. E.K. Abdalla, J.N. Vauthey Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 25 2008 421 429
63. R. Angitapalli, A.M. Litwin, P.R. Kumar Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer Oncology 76 2009 363 368
64. M.J. Overman, D.M. Maru, C. Charnsangavej Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury J Clin Oncol 28 2010 2549 2555
65. M. Klinger, S. Eipeldauer, S. Hacker Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases Eur J Surg Oncol 35 2009 515 520
66. D. Ribero, H. Wang, M. Donadon Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767 (Pubitemid 350250347)
67. B.R. Curtis, J. Kaliszewski, M.B. Marques Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin Am J Hematol 81 2006 193 198
68. L. Bozec, P. Bierling, P. Fromont Irinotecan-induced immune thrombocytopenia Ann Oncol 9 1998 453 455 (Pubitemid 28273041)
69. F. Pietrantonio, M. Di Bartolomeo, R. Buzzoni Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report Tumori 96 2010 154 156
70. M.A. Bautista, W.T. Stevens, C.S. Chen Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature J Hematol Oncol 3 2010 12
71. R. Fontao-Wendel, P.M. Hoff, A. Lazar Immune-mediated pancytopenia induced by oxaliplatin: a case report Transfusion 50 2010 1453 1459
72. H.J. Lenz Management and preparedness for infusion and hypersensitivity reactions Oncologist 12 2007 601 609
73. G. Brandi, M.A. Pantaleo, C. Galli Hypersensitivity reactions related to oxaliplatin (OHP) Br J Cancer 89 2003 477 481 (Pubitemid 37026428)
74. A. Gowda, R. Goel, J. Berdzik Hypersensitivity reactions to oxaliplatin: incidence and management Oncology (Williston Park) 18 2004 1671 1675 discussion 1676, 1680, 1683-4
75. R.R. Thomas, M.G. Quinn, B. Schuler Hypersensitivity and idiosyncratic reactions to oxaliplatin Cancer 97 2003 2301 2307 (Pubitemid 36444076)
76. D. Gammon, P. Bhargava, M.J. McCormick Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol Oncologist 9 2004 546 549 (Pubitemid 39332318)
77. L. Mis, N.H. Fernando, H.I. Hurwitz Successful desensitization to oxaliplatin Ann Pharmacother 39 2005 966 969 (Pubitemid 40570680)
78. E.I. Syrigou, E.M. Karapanagiotou, C.V. Alamara Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol Clin Colorectal Cancer 8 2009 106 109
79. M. Baur, H.R. Kienzer, T. Rath Extravasation of oxaliplatin (Eloxatin®) - clinical course Onkologie 23 2000 468 471
80. K.F. Foo, M. Michael, G. Toner A case report of oxaliplatin extravasation Ann Oncol 14 2003 961 962
81. J.G. Kennedy, J.P. Donahue, B. Hoang Vesicant characteristics of oxaliplatin following antecubital extravasation Clin Oncol (R Coll Radiol) 15 2003 237 239 (Pubitemid 36950004)
82. C. Pericay, A. Lopez, J.R. Soler Extravasation of oxaliplatin: an infrequent and irritant toxicity Clin Transl Oncol 11 2009 114 116
83. A. Kretzschmar, D. Pink, P. Thuss-Patience Extravasations of oxaliplatin J Clin Oncol 21 2003 4068 4069
84. M.L. de Lemos, S. Walisser Management of extravasation of oxaliplatin J Oncol Pharm Pract 11 2005 159 162